Intradialytic Hypotension Clinical Trial
Official title:
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor A Randomized, Double-blind, Placebo-controlled, Cross Over Explorative Study
Currently, there is no medication available to adequately treat patients undergoing hemodialysis who are suffering from intradialytic hypotension (IDH). Medical interventions such as Trendelenburg positioning, saline bolus administration, reduction of ultrafiltration rate, interruption of the hemodialysis, and other medical treatments are the methods of choice to treat the hypotensive condition of these patients and thus to maintain the systolic blood pressure. Patients suffering from IDH have a higher reported mortality rate due to the given stress on their cardiovascular system. New treatments, therefore, would give clinicians an additional alternative to current existing approaches and might help patients to maintain their blood pressure during hemodialysis. The main objective of the study is to evaluate the efficacy of icatibant in the prevention of systolic blood pressure (SBP) drop in patients on hemodialysis suffering from recurrent IDH episodes during hemodialysis.
Status | Recruiting |
Enrollment | 26 |
Est. completion date | December 1, 2025 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients = 18 to = 80 years of age - Patients with end-stage renal disease on hemodialysis (including hemodiafiltration) for at least 6 months, receiving 3 dialysis sessions per week and who are in a stable clinical condition per investigator's judgement - Patients on hemodialysis with at least 6 IDH episodes during the last 8 weeks based on medical record assessment - Pre-dialysis systolic blood pressure = 110 and = 170 mmHg assessed by two consecutive and averaged pre-HD blood pressure measurments - Patients adequately hemodialyzed with a Kt/V = 1.2 - Patients whose treatment regimen remained unchanged within 14 days prior to dosing (diet, medication, dry weight, treatment time, dialysate composition and temperature, dialysis shift, blood flow, and dialysate flow, vascular access) - Female subjects < 55 years of age to agree on effective contraception methods throughout the study period and who have a negative pregnancy test before initiating study activities - Body weight = 150 kg Exclusion Criteria: - Patients who have been hospitalized during the last 4 weeks before enrolment, except vascular access related hospitalization - Patients with known clinically evident inflammatory or infectious disease per investigator's evaluation - Severe anemia with a hemoglobin (Hb) < 8.0 g/dL at screening - Platelet count < 50 x 109/L - Hepatic disease associated with ALT > 3x ULN, or total bilirubin >2x ULN with direct bilirubin > 20% of the total bilirubin level - Known bleeding disorders e.g., von-Willebrand disease or Hemophilia A, B, C, etc. - Recent (<3 months before screening) thromboembolic event, e.g., acute coronary syndrome, stroke, or venous thrombosis embolism (except dialysis access thrombosis) - Recent (<3 months before screening) major surgery or scheduled major surgery during study participation - Scheduled living donor renal transplant during study participation - Persistent heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher - Receiving antiplatelet therapy except daily ASA = 150 mg/day - Receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure - Patients with significant pre-dialysis overload as defined by > 5kg above dry weight estimated by bioimpedance spectroscopy - Patient's life expectancy < 6 months per investigator's judgement |
Country | Name | City | State |
---|---|---|---|
United States | Vanderbilt Fresenius | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Vanderbilt University Medical Center | Pharvaris Netherlands B.V., Renal Research Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood pressure during hemodialysis | Average systolic blood pressure | 0-8 weeks | |
Secondary | Hypotension events | We will record the number of hypotensive events during hemodialysis. We expect a decrease of event in the treatment arm compared to placebo | 0-8 week | |
Secondary | Symptomatology associated with hypotension | At the end of each hemodialysis session in the cross-over main study, the presence of any symptoms associated with hypotension using a standardized questionnaire will be assessed. This questionnaire will include symptoms such as cramps, dizziness, nausea and fatigue rating, and will be scored according to the severity from 0 to 4 (none to severe) for the first listed symptoms, and according to the SONG-HD Fatigue scoring for the last listed symptom, respectively. | 0-8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02264522 -
Pilot Study Using a Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Hemodialysis Ultrafiltration
|
N/A | |
Recruiting |
NCT02583802 -
The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT00576524 -
Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis
|
Phase 2 | |
Not yet recruiting |
NCT05517993 -
Effect of Gui-Lu-Er-Xian-Jiao-Wan on Intradialytic Hypotension
|
Phase 2/Phase 3 | |
Completed |
NCT04180514 -
Applying Pulse Wave Analysis to Predict Intradialytic Hypotension
|
||
Completed |
NCT03916861 -
BIA Versus Physician Adjustment in Acute Kidney Injury Patients Requiring Renal Replacement Therapy
|
N/A | |
Completed |
NCT00257504 -
Central Blood Volume in Hypotensive Dialysis Patients
|
N/A | |
Enrolling by invitation |
NCT03080441 -
Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention
|
Phase 4 | |
Active, not recruiting |
NCT05905692 -
Evaluation of the Impact of L- Carnitine in Intradialytic Hypotension in Pediatric Patients on Regular Hemodialysis
|
Phase 3 | |
Completed |
NCT03057392 -
Head Out Water Immersion for Hemodynamic Stability During Dialysis
|
N/A | |
Recruiting |
NCT02210377 -
A Preliminary Randomized Study of Tianjiu (Auto-moxibustion) Effects in Patients With Intradialytic Hypotension
|
Phase 2 | |
Recruiting |
NCT05270759 -
Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy
|
||
Completed |
NCT02159625 -
Abdominal Compression Elastic Support (ACES)
|
N/A | |
Completed |
NCT01988181 -
Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study
|
N/A | |
Completed |
NCT06279156 -
Optimal Frequency of Total Body Water Measurements by Bioelectrical Impedance Analysis to Prevent Intradialytic Hypotension
|
N/A | |
Completed |
NCT03249532 -
Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis
|
N/A | |
Completed |
NCT03504943 -
Timing of Intradialytic Exercise and Its Impact on Intradialytic Hypotension
|
N/A | |
Completed |
NCT02719223 -
The Effect of On-Line Hemodiafiltration Versus High Flux Hemodialysis on Hemodynamic Parameters in Patients With Intra-Dialytic Hypotension
|
N/A | |
Recruiting |
NCT04163614 -
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05936710 -
Improved Hemodynamic Tolerance of Intermittent Hemodialysis Sessions in Intensive Care Unite Using Citrate- vs Acetate-based Dialysate
|
N/A |